Inovio Pharmaceuticals, Inc.
NASDAQ:INOBiotechnology
-$0.01 today
- Market cap
- $116.77M
- Beta
- 1.49
- P/E (TTM)
- -8.9
- EPS (TTM)
- -$0.12
Volume 11.56M
Average 2.73M
INO Account Payables
Amounts the company owes suppliers for goods and services received.
Inovio Pharmaceuticals, Inc.NASDAQ: INO
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 64.0% from a year ago
Account payables stood at $1.99M at the end of Q1 FY2026, down 64.0% from a year earlier and down 24.1% from the prior quarter. Over 3 fiscal years it compounded at -50.1% a year.
Context
- Account payables amounted to 4.0% of total assets at the end of Q1 FY2026, down 2.3 pp from a year earlier.
- Account payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -64.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.62M USD
- Year-over-year change
- -59.3%
- 4-year CAGR
- -44.7%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.62M | -59.3% |
| FY2024 | 2024-12-31 | 6.44M | +38.6% |
| FY2023 | 2023-12-31 | 4.65M | -78.0% |
| FY2022 | 2022-12-31 | 21.08M | -24.6% |
| FY2021 | 2021-12-31 | 27.97M | — |
Account Payables vs competitors
How INO compares with its peers on the latest reported figures
- INO's Mar 2026 account payables of $1.99M is the 6th highest of the 10 companies compared; the peer median is $2.34M.
- Its year-over-year change of -64.0% is the 9th highest of 10, against a peer median of -21.8%.
- Account payables amounts to 4.0% of total assets for INO, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $71.08M | +10.7% | +26.6% | 38.1% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.42M | +82.0% | +45.5% | 6.6% |
| Mar 2026 | $3.28M | -21.8% | -31.5% | 1.2% | |
| Mar 2026 | $2.5M | -43.9% | +38.7% | 0.9% | |
| Mar 2026 | $2.34M | +7.8% | -54.1% | 2.0% | |
| Mar 2026 | $1.99M | -64.0% | -50.1% | 4.0% | |
| Mar 2026 | $1.66M | +56.7% | -30.4% | 1.2% | |
| Mar 2026 | $1.42M | -38.8% | -26.1% | 0.6% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $1.2M | -54.6% | -10.6% | 13.5% |
| Mar 2026 | $217K | -87.7% | +3.9% | 0.4% | |
| Peer median (excluding INO) | $2.34M | -21.8% | -10.6% | 1.2% | |
Competitors are the stored peer set for INO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 71.14M | 46.33M | 14.31M | 65.81M | 44.27M |
| Short-term Investments | 330.17M | 206.67M | 130.98M | 28.3M | 14.24M |
| Net Receivables | 8.03M | 11.74M | 2.41M | 1.2M | 450 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 261.19K | 30.38M | 20.43K | 0 | 0 |
| Total Current Assets | 448.44M | 315.24M | 153.11M | 97.83M | 61.12M |
| Property, Plant & Equipment (Net) | 29.02M | 17.96M | 14.45M | 11.77M | 9.07M |
| Goodwill | 10.51M | 10.51M | 0 | 0 | 0 |
| Intangible Assets | 2.63M | 2.13M | 0 | 0 | 0 |
| Long-term Investments | 3.91M | 2.01M | 2.78M | 1.61M | 2.1M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.43M | 684.04K | 605.32K | 1.98M | 2.01M |
| Total Non-current Assets | 47.5M | 33.29M | 17.84M | 15.37M | 13.19M |
| Total Assets | 495.94M | 348.53M | 170.95M | 113.2M | 74.31M |
| Account Payables | 27.97M | 21.08M | 4.65M | 6.44M | 2.62M |
| Short-term Debt | 0 | 0 | 16.77M | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 21.63K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 20.71M | 15.14M | 9.95M | 23.26M | 36.44M |
| Total Current Liabilities | 65.74M | 96.87M | 42.57M | 35.33M | 43.67M |
| Long-term Debt | 14.96M | 16.61M | 0 | 0 | 0 |
| Deferred Tax Liabilities | 32.05K | 32.05K | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 64.36K | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 14.83K | 0 | 0 | 0 | 0 |
| Total Non-current Liabilities | 30.53M | 29.3M | 11.03M | 9.37M | 6.55M |
| Total Liabilities | 96.27M | 126.17M | 53.6M | 44.69M | 50.21M |
| Common Stock | 217.38K | 21.09K | 22.79K | 36.1K | 69K |
| Retained Earnings | (1.21B) | (1.49B) | (1.62B) | (1.73B) | (1.82B) |
| Accumulated OCI | (282.24K) | (698.74K) | (662.6K) | (675.67K) | (637.96K) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 399.67M | 222.36M | 117.35M | 68.5M | 24.1M |
| Total Debt | 33.02M | 32.07M | 30.21M | 11.87M | 9.37M |
| Net Debt | (38.12M) | (14.25M) | 15.9M | (53.95M) | (34.91M) |
Inovio Pharmaceuticals, Inc.
NASDAQ:INO
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.